Myology research highlights
RSS feedMadras motor neuron disease (MMND): A distinct clinical subgroup of childhood onset MND
Madras motor neuron disease (MMND), MMND variant (MMNDV) and Familial MMND (FMMND) have a unique geographic distribution predominantly reported from Southern India. The characteristic features are onset in young, weakness and wasting of limbs, multiple lower cranial nerve palsies and sensorineural hearing loss. There is a considerable overlap in the phenotype of MMND with Brown-Vialetto-Van … [Read more]
De novo INF2 mutations expand the genetic spectrum of hereditary neuropathy with glomerulopathy
This study aimed to identify mutations in the inverted formin-2 (INF2) gene in patients with Charcot-Marie-Tooth (CMT) disease combined with focal segmental glomerulosclerosis (FSGS) in order to expand the genetic and phenotypic spectrum. INF2 was sequenced in 5 patients with CMT disease and FSGS. Mutations were subsequently screened in family members of the index patient … [Read more]
AAV1.NT-3 gene therapy for Charcot-Marie-Tooth neuropathy
Charcot-Marie-Tooth (CMT) neuropathies represent a heterogeneous group of peripheral nerve disorders affecting 1 in 2500 persons. One variant, CMT1A, is a primary Schwann cell disorder, and represents the single most common variant. In previous studies the authors showed that neurotrophin-3 (NT-3) improved the tremblerJ (TrJ) mouse and also showed efficacy in CMT1A patients. Long-term treatment … [Read more]
Recessive TTN truncating mutations define novel forms of core myopathy with heart disease
Core myopathies (CM), the main non-dystrophic myopathies in childhood, remain genetically unexplained in many cases. Heart disease is not considered part of the typical CM spectrum. No congenital heart defect has been reported, and childhood-onset cardiomyopathy has been documented in only two CM families with homozygous mutations of the TTN gene. TTN encodes titin, a … [Read more]
Implication of Brugada syndrome in sudden death in DM1
In patients with myotonic dystrophy type 1 (DM1), the mechanisms underlying sudden cardiac death, which occurs in up to 1/3 of patients, are unclear. To study the potential role of Brugada syndrome in ventricular tachyarrhythmias and sudden death in DM1 patients, 914 adult patients included in the DM1 Heart Registry during 2000-2009 were screened for … [Read more]
Longitudinal in vivo muscle function analysis
Myotonic dystrophy is the most common adult muscle dystrophy. In view of emerging therapies, which use animal models as a proof of principle, the development of reliable outcome measures for in vivo longitudinal study of mouse skeletal muscle function is becoming crucial. To satisfy this need, the authors have developed a device to measure ankle … [Read more]
The TREAT-NMD Duchenne Muscular Dystrophy Registries
Duchenne muscular dystrophy (DMD) is an X-linked genetic disease, caused by the absence of the dystrophin protein. While many novel therapies are under development for DMD, there is currently no cure and affected individuals are often confined to a wheelchair by their teens and die in their twenties/thirties. DMD is a rare disease (prevalence < … [Read more]
Validation of a score tool to measure histological abnormalities in juvenile dermatomyositis
This study aimed to examine muscle biopsy tissue from patients with juvenile dermatomyositis (JDM) in order to test the reliability of a score tool designed to quantify the severity of histological abnormalities when applied to biceps humeri in addition to quadriceps femoris. Additionally, to evaluate whether elements of the tool correlate with clinical measures of … [Read more]
The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1
Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array on chromosome 4 to a size of 1-10 units. The residual number of D4Z4 units inversely correlates with clinical severity, but significant clinical variability exists. Each unit contains a copy of the DUX4 retrogene. Repeat contractions are associated with changes … [Read more]
FHL1: a therapeutic target for Duchenne muscular dystrophy?
Utrophin is a potential therapeutic target for the fatal muscle disease, Duchenne muscular dystrophy (DMD). In adult skeletal muscle, utrophin is restricted to the neuromuscular and myotendinous junctions and can compensate for dystrophin loss in mdx mice, a mouse model of DMD, but requires sarcolemmal localization. NFATc1-mediated transcription regulates utrophin expression and the LIM protein, … [Read more]